Recombinant EGFR (Zalutumumab Biosimilar) antibody

Catalog No. ABIN7487875

This anti-EGFR (Zalutumumab Biosimilar) antibody is a Mammalian Cells Monoclonal antibody detecting EGFR (Zalutumumab Biosimilar) in ELISA. Suitable for Human.

Quick Overview for Recombinant EGFR (Zalutumumab Biosimilar) antibody (ABIN7487875)

Target: EGFR (Zalutumumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This EGFR (Zalutumumab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-EGFR (Zalutumumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Zalutumumab Biosimilar - Anti-EGFR mAb

Characteristics: Antibody Type: IgG1-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1 kappa

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for EGFR (Zalutumumab Biosimilar)

Target: EGFR (Zalutumumab Biosimilar)

Target Type: Biosimilar

Background: HuMax-EGFr
Zalutumumab (proposed trade name HuMax-EGFR) is a high affinity, completely human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFR, also known as ErbB1/HER1). It is developed by Genmab and designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), a type of cancer. Zalutumumab is derived from transgenic mice immunized with A431-derived EGFR.

CAS-No: 667901-13-5